About Shukrapharmaceuticals
Shukrapharmaceuticals is a publicly listed company. Affordable generic pharmaceuticals are manufactured and distributed globally. The company has 115 employees. Its Indian entity Shukra Pharmaceuticals Limited reported revenue of ₹61.29 Cr. Its focus areas include Traditional Pharmaceuticals.
Company details
Generic medications are developed and produced by Shukrapharmaceuticals in the pharmaceutical sector, with emphasis on cost-effective methods. Manufacturing processes are aligned with strict quality controls, and regulatory approvals are obtained across international markets. The product lineup features injectables, oral solids, and capsules. Distribution efforts support healthcare access in various regions, though specific founding details remain unavailable.
- Employees 115
- Stage Public
- SectorsHealthcare
- Website shukrapharmaceuticals.com
- Legal Name Shukra Pharmaceuticals Ltd.
- Market Cap₹3,536 Cr
SHUKRAPHAR · NSE
- Share Price₹79.88
-0.03% today
- Revenue₹56.71 Cr
FY 2025-26 · +74.0% YoY
- EBITDA₹28.78 Cr
Margin 50.8%
- Net Profit₹22.05 Cr
FY 2025-26 · +130.2% YoY
- P/E (TTM)104.0x
P/B 35.0x
- ROE28.9%
ROCE 36.9%
- Debt / Equity0.06
Interest cover 4.5x
- Employee Count115
Associated legal entities of Shukrapharmaceuticals
Shukrapharmaceuticals operates through Shukra Pharmaceuticals Limited, a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Shukra Pharmaceuticals Limited Listed CIN L24231GJ1993PLC019079 | Active | 04 Mar 1993 | Ahmedabad, Gujarat | ₹61.3 Cr | 56 | 14 | View details |
Board of directors of Shukra Pharmaceuticals Limited (Shukrapharmaceuticals)
Shukra Pharmaceuticals Limited is the primary company behind Shukrapharmaceuticals. The board of Shukra Pharmaceuticals Limited currently have 12 directors; the longest-serving is Payal Sujay Mehta, appointed in 2012. 23 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Payal Sujay Mehta DIN 02145421 | Director | 23 May 2012 | 14 yrs 5 mo | Shukra Pharmaceuticals Limited |
| Dakshesh Rameshchandra Shah DIN 00561666 | Managing Director | 26 May 2012 | 14 yrs 5 mo | Shukra Pharmaceuticals Limited |
| Sonal Deepalbhai Gandhi DIN 07351479 | Director | 12 Aug 2023 | 3 yrs 2 mo | Shukra Pharmaceuticals Limited |
| Sanskruti Jayeshbhai Patel DIN 07108631 | Whole-time director | 16 Aug 2023 | 3 yrs 2 mo | Shukra Pharmaceuticals Limited |
| Sarjeevan Singh DIN 08258683 | Director | 16 Aug 2023 | 3 yrs 2 mo | Shukra Pharmaceuticals Limited |
| Dhruvin Shah DIN 08801616 | Whole-time director | 16 Aug 2023 | 3 yrs 2 mo | Shukra Pharmaceuticals Limited |
| Pinki Nirmal Sagar DIN 08113318 | Director | 25 Nov 2023 | 2 yrs 11 mo | Shukra Pharmaceuticals Limited |
| Anar Jayeshbhai Patel DIN 02588388 | Whole-time director | 10 Jul 2024 | 2 yrs 3 mo | Shukra Pharmaceuticals Limited |
| Jitendra Somchand Shah DIN 01609325 | Director | 10 Jul 2024 | 2 yrs 3 mo | Shukra Pharmaceuticals Limited |
| Shital Shah DIN 00561649 | Whole-time director | 25 Oct 2024 | 2 yrs | Shukra Pharmaceuticals Limited |
| Ritu Kapoor DIN 10334249 | Director | 25 Oct 2024 | 2 yrs | Shukra Pharmaceuticals Limited |
| Dinesh Chauhan DIN 11456530 | Additional Director | 30 Dec 2025 | 10 mo | Shukra Pharmaceuticals Limited |
People of Shukrapharmaceuticals
3 people are tracked at Shukrapharmaceuticals (1 in leadership, 2 in team); the tracked headcount is 115.
| Name | Role | Group |
|---|---|---|
Karnik Jashvantlal Shah | CEO | Leadership |
Vivek Ghate | Research And Development | Team |
Shubham Gaur | Business Development Manager | Team |
Complete people profiles for Shukrapharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Shukrapharmaceuticals
Shukrapharmaceuticals is a publicly listed company on the BSE with ticker symbol SHUKRAPHAR in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date30 Sep 1994
- Listed onBSE: 524632
- Listed entityShukra Pharmaceuticals Ltd.
- Exchange sectorHealth technology
- ISININE551C01044
- Share price₹31.87 (-4.98% on the day) · 2026-05-11
- Market capitalisation₹1,469 Cr
- Price to earnings63.4
- EPS (diluted, trailing year)₹0.50
- Dividend yield0.03%
- Volume (last session)116,008
- Analyst consensusNo rating
Financials of Shukrapharmaceuticals
Exchange-reported figures of Shukra Pharmaceuticals Limited, the listed company behind Shukrapharmaceuticals (NSE: SHUKRAPHAR).
Financial Highlights
FY 2025-26 · ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Income statement | ||
| Revenue | 56.71 | 32.59 |
| Revenue growth | +74.0% | - |
| EBITDA | 28.78 | 12.72 |
| EBITDA margin | +50.8% | +39.0% |
| Profit before tax | 28.77 | 13.34 |
| Net profit | 22.05 | 9.58 |
| Net profit margin | +38.9% | +29.4% |
| EPS (₹) | 0.50 | 0.22 |
| Balance sheet | ||
| Total assets | 94.97 | 67.14 |
| Net worth | 89.84 | 62.84 |
| Total debt | 5.02 | 4.18 |
| Cash & bank | 5.92 | 12.12 |
| Net working capital | 62.49 | 49.20 |
| Cash flow | ||
| Cash from operations | 3.15 | 7.92 |
| Cash from investing | (14.18) | (1.26) |
| Cash from financing | 4.83 | (4.52) |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 44.20 | 23.52 | 6.32 | 39.13 | 5.88 | 5.39 | 13.27 |
| Revenue growth (YoY) | +651.7% | +336.4% | -52.4% | - | - | - | - |
| Other income | 0.57 | 0.54 | 0.95 | 0.82 | 1.71 | 1.11 | 1.47 |
| EBITDA | 18.70 | 19.14 | 0.70 | 27.13 | (0.42) | 1.32 | 7.32 |
| EBITDA margin | +42.3% | +81.4% | +11.1% | +69.3% | -7.1% | +24.5% | +55.2% |
| Depreciation | 1.12 | 1.08 | 1.01 | 0.84 | 0.81 | 0.79 | 0.94 |
| Interest | 0.33 | 0.43 | 0.26 | 0.28 | 0.29 | 0.27 | 0.27 |
| Profit before tax | 17.82 | 18.17 | 0.38 | 26.83 | 0.19 | 1.37 | 7.58 |
| Tax | 5.11 | 5.21 | 2.10 | 6.46 | (2.18) | 0.35 | 2.18 |
| Net profit | 12.71 | 12.96 | (1.72) | 20.37 | 2.37 | 1.02 | 5.40 |
| EPS (₹) | 0.29 | 0.30 | (0.04) | 0.47 | 0.05 | 0.02 | 0.12 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 56.71 | 32.59 | 74.57 | 58.83 | 20.49 | 11.20 | 11.84 |
| Revenue growth | +74.0% | -56.3% | +26.8% | +187.1% | +83.0% | -5.4% | - |
| EBITDA | 28.73 | 12.72 | 19.40 | 5.35 | 2.89 | 1.24 | 1.52 |
| EBITDA margin | +50.7% | +39.0% | +26.0% | +9.1% | +14.1% | +11.1% | +12.8% |
| Profit before tax | 28.78 | 13.34 | 19.88 | 4.43 | 1.02 | 0.10 | 0.15 |
| Net profit | 22.06 | 9.58 | 18.54 | 4.39 | 0.75 | 0.14 | (0.01) |
| Net profit margin | +38.9% | +29.4% | +24.9% | +7.5% | +3.7% | +1.3% | -0.1% |
| EPS (₹) | 0.50 | 0.22 | 16.93 | 11.26 | 4.79 | 1.20 | 0.23 |
| Balance sheet | |||||||
| Total assets | 94.97 | 67.14 | 60.91 | 30.49 | 19.73 | 25.37 | 23.46 |
| Net worth | 89.84 | 62.84 | 57.64 | 25.29 | 16.35 | 15.60 | 15.42 |
| Total debt | 5.02 | 4.18 | 3.16 | 5.08 | 3.38 | 9.77 | 8.05 |
| Cash & bank | 5.92 | 12.12 | 9.98 | 3.97 | 0.29 | 0.50 | 0.13 |
| Net working capital | 62.49 | 49.20 | 42.56 | 11.89 | 3.74 | 9.02 | 7.48 |
| Cash flow | |||||||
| Cash from operations | 3.15 | 7.92 | (5.20) | 3.17 | 7.99 | 0.54 | 1.24 |
| Cash from investing | (14.18) | (1.26) | (1.20) | (4.43) | (1.53) | (1.89) | (3.36) |
| Cash from financing | 4.83 | (4.52) | 12.41 | 4.94 | (6.68) | 1.74 | 1.99 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 44.20 | 23.52 | 6.30 | 39.13 | 5.88 | 5.39 | 13.27 | 10.58 |
| Revenue growth (YoY) | +651.7% | +336.4% | -52.5% | +269.9% | +5.8% | +69.5% | - | - |
| Other income | 0.57 | 0.54 | 0.95 | 0.82 | 1.71 | 1.11 | 1.47 | 1.01 |
| Total expenses | 22.19 | 2.32 | 5.62 | 12.00 | 6.30 | 4.07 | 5.95 | 6.65 |
| EBITDA | 22.01 | 21.20 | 0.68 | 27.13 | (0.42) | 1.32 | 7.32 | 3.93 |
| EBITDA margin | +49.8% | +90.1% | +10.8% | +69.3% | -7.1% | +24.5% | +55.2% | +37.1% |
| Depreciation | 1.12 | 1.07 | 1.01 | 0.84 | 0.81 | 0.79 | 0.94 | 0.70 |
| Interest | 0.33 | 0.43 | 0.26 | 0.28 | 0.29 | 0.27 | 0.27 | 0.15 |
| Profit before tax | 21.13 | 20.24 | 0.36 | 26.83 | 0.19 | 1.37 | 7.58 | 4.09 |
| Tax | 5.11 | 5.21 | 2.10 | 6.46 | (2.18) | 0.35 | 2.18 | 0.93 |
Financial Statements
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 44.20 | 23.52 | 6.32 | 39.13 | 5.88 | 5.39 | 13.27 |
| Revenue growth (YoY) | +651.7% | +336.4% | -52.4% | - | - | - | - |
| Other income | 0.57 | 0.54 | 0.95 | 0.82 | 1.71 | 1.11 | 1.47 |
| EBITDA | 18.70 | 19.14 | 0.70 | 27.13 | (0.42) | 1.32 | 7.32 |
| EBITDA margin | +42.3% | +81.4% | +11.1% | +69.3% | -7.1% | +24.5% | +55.2% |
| Depreciation | 1.12 | 1.08 | 1.01 | 0.84 | 0.81 | 0.79 | 0.94 |
| Interest | 0.33 | 0.43 | 0.26 | 0.28 | 0.29 | 0.27 | 0.27 |
| Profit before tax | 17.82 | 18.17 | 0.38 | 26.83 | 0.19 | 1.37 | 7.58 |
| Tax | 5.11 | 5.21 | 2.10 | 6.46 | (2.18) | 0.35 | 2.18 |
| Net profit | 12.71 | 12.96 | (1.72) | 20.37 | 2.37 | 1.02 | 5.40 |
| EPS (₹) | 0.29 | 0.30 | (0.04) | 0.47 | 0.05 | 0.02 | 0.12 |
| Particulars | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Revenue | 56.71 | 32.59 |
| Revenue growth | +74.0% | - |
| Other income | 4.58 | 4.21 |
| Total expenses | 27.93 | 19.87 |
| Employee cost | 6.40 | 5.47 |
| EBITDA | 28.78 | 12.72 |
| EBITDA margin | +50.8% | +39.0% |
| Depreciation | 3.44 | 3.00 |
| Interest | 1.15 | 0.59 |
| Profit before tax | 28.77 | 13.34 |
| Tax | 6.72 | 3.76 |
| Net profit | 22.05 | 9.58 |
| Net profit margin | +38.9% | +29.4% |
| EPS (₹) | 0.50 | 0.22 |
| Particulars | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Equity & liabilities | ||
| Share capital | 43.79 | 43.79 |
| Reserves & surplus | 40.66 | 19.05 |
| Shareholders' funds (net worth) | 89.84 | 62.84 |
| Minority interest | 0.00 | 0.00 |
| Secured loans | 4.33 | 2.70 |
| Unsecured loans | 0.69 | 1.48 |
| Total debt | 5.02 | 4.18 |
| Total liabilities | 94.97 | 67.14 |
| Assets | ||
| Gross block | 49.19 | 43.42 |
| Net block | 21.72 | 19.39 |
| Capital work in progress | 11.91 | 1.95 |
| Investments | 0.03 | 0.00 |
| Inventories | 13.90 | 9.95 |
| Sundry debtors | 22.95 | 8.77 |
| Cash & bank balances | 5.92 | 12.12 |
| Loans & advances | 40.98 | 34.59 |
| Total current assets | 83.75 | 65.43 |
| Total current liabilities | 21.26 | 16.23 |
| Net working capital | 62.49 | 49.20 |
| Total assets | 94.97 | 67.14 |
| Particulars | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Opening cash | 12.12 | 9.98 |
| Net cash from operating activities | 3.15 | 7.92 |
| Net cash from investing activities | (14.18) | (1.26) |
| Net cash from financing activities | 4.83 | (4.52) |
| Net change in cash | (6.20) | 2.14 |
| Closing cash | 5.92 | 12.12 |
| Particulars | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Growth | ||
| Sales growth | +74.0% | - |
| EBITDA growth | +126.3% | - |
| PBT growth | +115.7% | +9997.0% |
| Net income growth | +130.2% | - |
| Profitability & leverage | ||
| Net income margin | +38.9% | +29.4% |
| Return on capital employed | +36.9% | +20.8% |
| Return on net worth | +28.9% | +15.3% |
| Debt / equity | 0.06 | 0.07 |
| Long-term debt / equity | 0.04 | 0.05 |
| Interest cover | 4.54 | 6.07 |
| Efficiency & per share | ||
| Fixed asset turnover | 1.22 | 0.75 |
| Inventory turnover | 4.76 | 3.28 |
| Debtors turnover | 3.58 | 3.72 |
| EPS (₹) | 0.50 | 0.22 |
| Dividend per share (₹) | 0.01 | 0.01 |
| Book value per share (₹) | 1.93 | 1.44 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 44.20 | 23.52 | 6.30 | 39.13 | 5.88 | 5.39 | 13.27 | 10.58 |
| Revenue growth (YoY) | +651.7% | +336.4% | -52.5% | +269.9% | +5.8% | +69.5% | - | - |
| Other income | 0.57 | 0.54 | 0.95 | 0.82 | 1.71 | 1.11 | 1.47 | 1.01 |
| Total expenses | 22.19 | 2.32 | 5.62 | 12.00 | 6.30 | 4.07 | 5.95 | 6.65 |
| EBITDA | 22.01 | 21.20 | 0.68 | 27.13 | (0.42) | 1.32 | 7.32 | 3.93 |
| EBITDA margin | +49.8% | +90.1% | +10.8% | +69.3% | -7.1% | +24.5% | +55.2% | +37.1% |
| Depreciation | 1.12 | 1.07 | 1.01 | 0.84 | 0.81 | 0.79 | 0.94 | 0.70 |
| Interest | 0.33 | 0.43 | 0.26 | 0.28 | 0.29 | 0.27 | 0.27 | 0.15 |
| Profit before tax | 21.13 | 20.24 | 0.36 | 26.83 | 0.19 | 1.37 | 7.58 | 4.09 |
| Tax | 5.11 | 5.21 | 2.10 | 6.46 | (2.18) | 0.35 | 2.18 | 0.93 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 56.71 | 32.59 | 74.57 | 58.83 | 20.49 | 11.20 | 11.84 |
| Revenue growth | +74.0% | -56.3% | +26.8% | +187.1% | +83.0% | -5.4% | - |
| Other income | 4.58 | 4.21 | 2.82 | 1.20 | 0.08 | 0.36 | 0.11 |
| Total expenses | 27.98 | 19.87 | 55.17 | 53.48 | 17.60 | 9.96 | 10.32 |
| Employee cost | 0.00 | 5.47 | 5.02 | 4.41 | 4.57 | 3.75 | 4.34 |
| EBITDA | 28.73 | 12.72 | 19.40 | 5.35 | 2.89 | 1.24 | 1.52 |
| EBITDA margin | +50.7% | +39.0% | +26.0% | +9.1% | +14.1% | +11.1% | +12.8% |
| Depreciation | 3.44 | 3.00 | 2.05 | 1.84 | 1.66 | 1.47 | 1.48 |
| Interest | 1.09 | 0.59 | 0.29 | 0.28 | 0.29 | 0.03 | 0.00 |
| Profit before tax | 28.78 | 13.34 | 19.88 | 4.43 | 1.02 | 0.10 | 0.15 |
| Tax | 6.72 | 3.76 | 1.34 | 0.04 | 0.27 | (0.09) | 0.14 |
| Net profit | 22.06 | 9.58 | 18.54 | 4.39 | 0.75 | 0.14 | (0.01) |
| Net profit margin | +38.9% | +29.4% | +24.9% | +7.5% | +3.7% | +1.3% | -0.1% |
| EPS (₹) | 0.50 | 0.22 | 16.93 | 11.26 | 4.79 | 1.20 | 0.23 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 43.79 | 43.79 | 10.95 | 3.91 | 1.57 | 1.57 | 1.57 |
| Reserves & surplus | 40.66 | 19.05 | 46.69 | 21.38 | 14.78 | 14.03 | 13.85 |
| Shareholders' funds (net worth) | 89.84 | 62.84 | 57.64 | 25.29 | 16.35 | 15.60 | 15.42 |
| Secured loans | 4.33 | 2.70 | 1.75 | 2.21 | 1.10 | 0.66 | 0.00 |
| Unsecured loans | 0.69 | 1.48 | 1.41 | 2.87 | 2.28 | 9.11 | 8.05 |
| Total debt | 5.02 | 4.18 | 3.16 | 5.08 | 3.38 | 9.77 | 8.05 |
| Total liabilities | 94.97 | 67.14 | 60.91 | 30.49 | 19.73 | 25.37 | 23.46 |
| Assets | |||||||
| Gross block | 49.19 | 43.42 | 40.97 | 39.57 | 35.07 | 33.53 | 31.74 |
| Net block | 21.72 | 19.39 | 19.95 | 20.24 | 17.58 | 17.70 | 17.38 |
| Capital work in progress | 11.91 | 1.95 | 1.66 | 1.66 | 1.66 | 1.66 | 1.66 |
| Investments | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.19 | 0.05 |
| Inventories | 13.90 | 9.95 | 2.31 | 3.16 | 3.95 | 1.68 | 1.39 |
| Sundry debtors | 22.95 | 8.77 | 24.51 | 30.19 | 7.40 | 9.75 | 7.95 |
| Cash & bank balances | 5.92 | 12.12 | 9.98 | 3.97 | 0.29 | 0.50 | 0.13 |
| Loans & advances | 40.98 | 34.59 | 19.42 | 15.76 | 4.23 | 4.13 | 4.99 |
| Total current assets | 83.75 | 65.43 | 56.22 | 53.08 | 15.87 | 16.06 | 14.46 |
| Total current liabilities | 21.26 | 16.23 | 13.66 | 41.19 | 12.13 | 7.04 | 6.98 |
| Net working capital | 62.49 | 49.20 | 42.56 | 11.89 | 3.74 | 9.02 | 7.48 |
| Total assets | 94.97 | 67.14 | 60.91 | 30.49 | 19.73 | 25.37 | 23.46 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 12.12 | 9.98 | 3.97 | 0.29 | 0.50 | 0.13 | 0.25 |
| Net cash from operating activities | 3.15 | 7.92 | (5.20) | 3.17 | 7.99 | 0.54 | 1.24 |
| Net cash from investing activities | (14.18) | (1.26) | (1.20) | (4.43) | (1.53) | (1.89) | (3.36) |
| Net cash from financing activities | 4.83 | (4.52) | 12.41 | 4.94 | (6.68) | 1.74 | 1.99 |
| Net change in cash | (6.20) | 2.14 | 6.01 | 3.68 | (0.21) | 0.38 | (0.12) |
| Closing cash | 5.92 | 12.12 | 9.98 | 3.97 | 0.29 | 0.50 | 0.13 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +74.0% | -56.3% | +26.8% | +187.1% | +83.0% | -5.4% | - |
| EBITDA growth | +125.9% | -34.4% | +262.6% | +85.1% | +133.1% | -18.4% | - |
| PBT growth | +115.7% | -32.9% | +348.8% | +334.3% | +920.0% | -33.3% | -79.5% |
| Net income growth | +130.3% | -48.3% | +322.3% | +485.3% | +435.7% | +1500.0% | - |
| Revenue CAGR (3Y) | -1.2% | +16.7% | +88.1% | +70.6% | +53.6% | +27.8% | +32.1% |
| EBITDA CAGR (3Y) | +75.2% | +63.9% | +150.1% | +52.1% | +20.5% | -8.2% | +1.4% |
| Profitability & leverage | |||||||
| Net income margin | +38.9% | +29.4% | +24.9% | +7.5% | +3.7% | +1.7% | +0.1% |
| Return on capital employed | +36.9% | +21.8% | +44.2% | +18.8% | +5.8% | +1.4% | +0.4% |
| Return on net worth | +28.9% | +15.9% | +44.7% | +21.2% | +4.7% | +0.9% | +0.1% |
| Debt / equity | 0.06 | 0.06 | 0.10 | 0.20 | 0.41 | 0.57 | 0.46 |
| Long-term debt / equity | 0.04 | 0.05 | 0.08 | 0.17 | 0.40 | 0.57 | 0.46 |
| Interest cover | 4.54 | 6.07 | 1.67 | 7.98 | 23.58 | -13.04 | 0.00 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 1.22 | 0.77 | 1.85 | 1.58 | 0.60 | 0.34 | 0.46 |
| Inventory turnover | 4.76 | 5.32 | 27.27 | 16.55 | 7.28 | 7.30 | 16.54 |
| Debtors turnover | 3.58 | 1.96 | 2.73 | 3.13 | 2.39 | 1.27 | 2.06 |
| EPS (₹) | 0.50 | 0.22 | 16.93 | 11.26 | 4.79 | 1.20 | 0.23 |
| Dividend per share (₹) | 0.01 | 0.01 | 1.00 | 0.50 | 0.50 | 0.00 | 0.00 |
| Book value per share (₹) | 1.93 | 1.44 | 52.65 | 64.63 | 104.43 | 99.63 | 98.43 |
Web traffic of Shukrapharmaceuticals
The website of Shukrapharmaceuticals (shukrapharmaceuticals.com) receives about 3.6K visits a month.
- Monthly visits3.6K
▼ 77.9% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Shukrapharmaceuticals
Complete news archive for Shukrapharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Shukrapharmaceuticals
Shukrapharmaceuticals has 115 employees.
The primary company behind Shukrapharmaceuticals, Shukra Pharmaceuticals Limited, reported revenue of ₹61.29 Cr for FY 2026, up 74% year on year.
Generic medications are developed and produced by Shukrapharmaceuticals in the pharmaceutical sector, with emphasis on cost-effective methods. Manufacturing processes are aligned with strict quality controls, and regulatory approvals are obtained across international markets. The product lineup features injectables, oral solids, and capsules. Distribution efforts support healthcare access in various regions, though specific founding details remain unavailable.
Yes, Shukrapharmaceuticals is publicly traded on BSE under the ticker symbol SHUKRAPHAR.
Shukrapharmaceuticals operates through Shukra Pharmaceuticals Limited.
The legal entities of Shukrapharmaceuticals currently have 13 directors, including Payal Sujay Mehta, Dakshesh Rameshchandra Shah, Dinesh Chauhan and others.